Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Gamida Cell Ltd. (GMDA) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/24/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER"
11/18/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER"
11/15/2021 6-K Quarterly results
Docs: "Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of November 2021 Commission File Number 001-38716 GAMIDA CELL LTD. 5 Nahum Heftsadie Street Givaat Shaul, Jerusalem 91340 Israel Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101: ☐ Other Events",
"Gamida Cell Reports Third Quarter 2021 Financial Results and Provides Company Update",
"INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Interim Consolidated Statements of Financial Position 3 – 4 Interim Consolidated Statements of Comprehensive Loss 5 Interim Consolidated Statements of Changes in Equity 6 – 8 Interim Consolidated Statements of Cash Flows 9 – 10 Notes to Interim Consolidated Financial Statements 11 – 21"
11/12/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Gamida Cell Provides Update on Pre-BLA Meeting with FDA for Omidubicel"
10/26/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today’ s Virtual R&D Day"
10/12/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Notice of the Annual Meeting (the “Meeting”) of shareholders of Gamida Cell Ltd. and Proxy Statement for the Meeting, each",
"Notice of the Annual Meeting (the “Meeting”) of shareholders of Gamida Cell Ltd. and Proxy Statement for the Meeting, each",
"Proxy card for use in connection with the Meeting"
08/13/2021 6-K Quarterly results
Docs: "Unaudited Interim Consolidated Financial Statements of June 30, 2021",
"Gamida Cell Reports Second Quarter 2021 Financial Results and Provides Company Update",
"Unaudited Interim Consolidated Financial Statements of June 30, 2021"
08/03/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER"
06/25/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "CURRENT REPORT"
06/07/2021 6-K Quarterly results
05/21/2021 6-K Quarterly results
05/11/2021 6-K Quarterly results
03/09/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Gamida Cell Reports Full Year 2020 Financial Results and Provides Company Update"
02/16/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Indenture dated February 16, 2021, between Gamida Cell Inc., as the Issuer, Gamida Cell Ltd., as the Guarantor, and Wilmington Savings Fund Society, FSB, as Trustee",
"Note Purchase Agreement dated February 15, 2021, between Gamida Cell Ltd., Gamida Cell Inc. and the entities listed on the Schedule of Buyers attached thereto",
"Registration Rights Agreement dated February 16, 2021, by and between Gamida Cell Ltd. and the entities listed on the signature pages thereto",
"Gamida Cell Announces $75 Million Financing with Highbridge Capital Management"
02/10/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 2021 TCT Meetings of ASTCT and CIBMTR"
12/21/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Underwriting Agreement, by and among Gamida Cell Ltd. and Piper Sandler & Co. and Evercore Group L.L.C., as representatives of the several underwriters named therein",
"Opinion of Meitar | Law Offices",
"Gamida Cell Announces Pricing of $65 Million Public Offering of Ordinary Shares",
"Gamida Cell Announces Closing of $75 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares"
12/17/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Gamida Cell Announces Launch of Public Offering of Ordinary Shares"
12/14/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Gamida Cell Provides Regulatory Update on Biologics License Application for Omidubicel"
12/09/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Gamida Cell Provides Pipeline Update, Including Detailed Results of Pivotal Phase 3 Clinical Study of Omidubicel, and Prepares to Start BLA Submission by End of 2020",
"Presentation, Inspired to Cure: Pipeline Deep Dive"
12/08/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "CURRENT REPORT OF FOREIGN ISSUER",
"Gamida Cell Presents Updated, Expanded Results from Phase 1study of Natural Killer Cell Therapy GDA-201 at ASH Annual Meeting and Exposition"
11/10/2020 6-K Quarterly results
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Gamida Cell Reports Third Quarter 2020 Financial Results and Provides Company Update"
11/05/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Gamida Cell Announces Data to Be Presented at 62nd ASH Annual Virtual Meeting"
11/02/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"FOR RELEASE ON MONDAY, NOVEMBER 2, 2020, AT 8:01 A.M. ET"
10/13/2020 6-K Quarterly results
10/06/2020 6-K Quarterly results
09/14/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER"
09/10/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Gamida Cell Presents Analysis of Observational Data Demonstrating the Impact of Donor Age in Hematopoietic Stem Cell Transplant Outcomes at the Virtual Cord Blood Connect Meeting"
08/12/2020 6-K Quarterly results
08/06/2020 6-K Quarterly results
07/21/2020 6-K Quarterly results
07/13/2020 6-K Quarterly results
05/26/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Gamida Cell Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares"
05/21/2020 6-K Quarterly results
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Gamida Cell Reports First Quarter 2020 Financial Results and Provides Company Update"
05/20/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Underwriting Agreement, by and among Gamida Cell Ltd. and Piper Sandler & Co., Evercore Group L.L.C., as representatives of the several underwriters named therein",
"Opinion of Meitar │Law Offices",
"Gamida Cell Announces Pricing of $60 Million Public Offering of Ordinary Shares"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy